Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study
Christian Junghanß(University of Rostock), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Michael Boeckh(Fred Hutch Cancer Center), Thomas R. Chauncey(City Of Hope National Medical Center), Lawrence Corey(Fred Hutch Cancer Center), Brenda M. Sandmaier(University of Washington), Peter A. McSweeney(Mesoblast (United States)), Marie-Térèse Little(Scripps Research Institute), Rachel A. Carter(Bloodworks Northwest), Michael B. Maris(Colorado Blood Cancer Institute), David G. Maloney(Fred Hutch Cancer Center)
Cited by 241
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k